President Donald Trump is poised to sign an executive order aimed at significantly expanding access to cannabis. This anticipated move would represent a considerable shift in U.S. drug policy, particularly given that cannabis has been classified as a Schedule I narcotic since 1971.
Key Changes in Cannabis Classification
The executive order is expected to reclassify cannabis from Schedule I to Schedule III. This new classification aligns cannabis with drugs such as Tylenol with codeine. Although cannabis will still remain illegal under federal law, this change would open doors for increased research into its potential medical benefits.
According to the U.S. Drug Enforcement Agency (DEA), Schedule III drugs have a “moderate to low potential for physical and psychological dependence.” This reclassification may also positively impact tax regulations for state-licensed cannabis dispensaries, allowing them more deductions not currently available for Schedule I products.
Potential Program for Older Americans
- The announcement may introduce a pilot program allowing reimbursement for cannabidiol (CBD) for older adults.
- This program is aimed at reimbursing certain medical expenses, including those related to cancer treatments.
Historical Context and Current Sentiment
In recent years, a growing number of U.S. states have approved cannabis for medical use, while 24 states have legalized it for recreational use. Trump’s intent to modify cannabis classification stems from his belief in the necessity of facilitating research that remains restricted by its current categorization. Earlier this week, he stated he was “considering” reclassification due to the “tremendous amounts of research that can’t be done unless you reclassify.”
Trump’s reclassification proposal, however, has faced considerable pushback. A group of 22 Republican senators sent an open letter expressing concerns over marijuana use, suggesting it could hinder economic recovery and may have health risks. They highlighted the risks associated with impaired judgment linked to cannabis consumption.
Public Opinion on Marijuana Legalization
Despite the resistance from some lawmakers, polls indicate that a majority of Americans support the legalization of marijuana. A Gallup poll conducted in November revealed that 64% of respondents favor legalization. Notably, however, support among Republicans saw a decline, reflecting a 13-point drop compared to previous years.
As this pivotal executive order looms on the horizon, the implications for U.S. drug policy and public health discussions continue to evolve. Trump’s approach signals a potential new era in how the federal government views cannabis usage and its impact on society.
